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RESUMO
Análise da Incidência e Preditores Clínicos e 
Ecocardiográficos do Refluxo Paraprotético Aórtico 
após o Implante de Prótese Aórtica Transcateter
Introdução: A incidência de refluxo paraprotético (RPP) parece 
maior entre os pacientes submetidos a implante de prótese 
aórtica transcateter e sua potencial associação com aumento da 
mortalidade tardia tem suscitado preocupação na comunidade 
científica. Nosso objetivo foi avaliar a incidência e o impacto 
clínico e estabelecer preditores do RPP em nossa casuística. 
Métodos: Entre julho de 2009 e fevereiro de 2013, 112 pacientes 
foram submetidos a implante de prótese aórtica transcateter. O 
grau do RPP pós-procedimento foi avaliado segundo os critérios 
do VARC 2. Dividiu-se a população em grupo RPP ausente/RPP 
discreto e grupo RPP moderado/RPP grave. Resultados: A média 
da idade foi de 82,5 ± 3,9 anos, 58,9% eram do sexo feminino 
e o EuroSCORE logístico foi de 23,6 ± 13,4. Houve queda do 
gradiente sistólico médio (54,7 ± 15,3 mmHg vs. 11,7 ± 4 
mmHg; P < 0,01) e ganho da área valvar aórtica (0,66 ± 0,15 
cm² vs. 1,8 ± 0,3 cm²; P < 0,01). Ao final do procedimento, 
46,4% não apresentaram RPP, e RRP discreto ou moderado foi 
observado em 42% e 11,6% dos pacientes. Nenhum paciente 
ABSTRACT
Background: The incidence of paravalvular aortic regurgitation 
(PAR) seems higher among patients submitted to transcatheter 
aortic valve implantation and its potential association with an 
increased late mortality has raised concerns in the scientific 
community. Our objective was to evaluate the incidence and 
clinical impact of PAR and establish PAR predictors in our 
patient population. Methods: Between July/2009 and Febru-
ary/ 2013, 112 patients were submitted to transcatheter aortic 
valve implantation. The degree of PAR after the procedure was 
assessed according to the VARC 2 criteria. The population was 
divided into no/mild PAR group and moderate/severe PAR 
group. Results: Mean age was 82.5 + 3.9 years, 58.9% were 
female and the logistic EuroSCORE was 23.6 ± 13.4. There 
was a decrease in the mean systolic gradient (54.7 ± 15.3 
mmHg vs 11.7 ± 4 mmHg; P < 0.01) and a gain in the aortic 
valve area (0.66 ± 0.15 cm² vs 1.8 ± 0.3 cm²; P < 0.01). At 
the end of the procedure 46.4% did not have PAR, and mild 
or moderate PAR was observed in 42% and 11.6% of the 
patients. No patient presented severe PAR. Multivariate analysis 
identified male gender [odds ratio (OR) 5.85, confidence in-
terval (CI] 1.29-26.7; P = 0.022), previous percutaneous aortic 
valvuloplasty (OR 18.44, CI 2.30-147.85; P = 0.006), ejection 
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apresentou RPP grave. A análise multivariada identificou sexo 
masculino [odds ratio (OR) 5,85, intervalo de confiança (IC] 
1,29-26,7; P = 0,022), valvoplastia aórtica percutânea prévia (OR 
18,44, IC 2,30-147,85; P = 0,006), fração de ejeção < 35% (OR 
4,160, IC 1,014-17,064; P = 0,048) e presença de hipertensão 
pulmonar grave (OR 7,649, IC 1,86-31,51; P = 0,005) como 
preditores independentes de RPP moderado/grave. Conclusões: A 
incidência de RPP moderado/grave foi baixa e comparável à de 
outras casuísticas. Sexo masculino, antecedente de valvoplastia 
aórtica percutânea prévia, presença de hipertensão pulmonar 
grave e disfunção ventricular esquerda grave foram preditores 
independentes dessa complicação.
DESCRITORES: Insuficiência da valva aórtica. Estenose da 
valva aórtica. Cateteres cardíacos. Implante de prótese de 
valva cardíaca.
fraction < 35% (OR 4.160, CI 1.014-17.064; P = 0.048) and 
the presence of severe pulmonary hypertension (OR 7.649, CI 
1.86-31.51; P = 0.005) as independent predictors of moderate/
severe PAR. Conclusions: The incidence of moderate/severe 
PAR was low and comparable to other studies. Male gender, 
history of prior percutaneous aortic valvuloplasty, presence 
of severe pulmonary hypertension and severe left ventricular 
dysfunction were independent predictors of this complication.
 
 
 
 
 
DESCRIPTORS: Aortic valve insufficiency. Aortic valve stenosis. 
Cardiac catheters. Heart valve prosthesis implantation.
I n recent years, the implantation of a transcatheter aortic valve prosthesis has become the treatment of choice for patients with severe symptomatic aortic 
stenosis considered inoperable,1 and an effective alter-
native in patients at high surgical risk.2
However, the incidence of paravalvular aortic re-
gurgitation (PAR) appears to be higher among patients 
submitted to transcatheter aortic valve implantation 
than after surgical aortic valve replacement,1,2 and its 
potential association with increased late mortality3 has 
raised concern in the international scientific community; 
PAR is considered the downfall of transcatheter aortic 
prosthesis implantation.4
The present study aimed to evaluate the incidence, 
severity, and clinical impact of PAR in patients under-
going transcatheter aortic prosthesis implantation at 
two institutions in the State of São Paulo, Brazil, and 
to try to establish the clinical and echocardiographic 
predictors of this serious problem.
METHODS
Subjects and procedure
This retrospective study included all symptomatic 
patients with severe aortic stenosis, considered to be at 
high surgical risk/inoperable, submitted to transcatheter 
aortic prosthesis implantation at Instituto de Cardiolo-
gia Dante Pazzanese and at Hospital do Coração da 
Associação do Sanatório Sírio between June 2009 and 
February 2013.
As part of the pre-intervention assessment, patients 
underwent computed tomography, angiography of the 
heart, aorta, and iliac arteries; coronary angiography; 
and transthoracic echocardiography. Based on the 
results of these tests, and after discussing with the lo-
cal heart team, the access route was chosen, and the 
type and diameter of the prosthesis to be implanted 
was established. Three types of prosthesis were used: 
CoreValve (Medtronic – Minneapolis, USA) by trans-
femoral, trans-subclavian, or transaortic approach; 
SAPIEN XT™ (Edwards Lifesciences – Irvine, California, 
United States), by transfemoral or transapical approach; 
and Acurate TF™ (Symetis Inc. – Geneva, Switzerland) 
by transfemoral approach.
All procedures were performed under general anes-
thesia and guided by transesophageal echocardiography. 
After left ventricular catheterisation, aortic balloon val-
vuloplasty was performed in cases in which the SAPIEN 
XT™ and Acurate TF™ prostheses were used or, when 
necessary, in cases in which the CoreValve prosthesis 
was used. Subsequently, the prosthesis was implanted, and 
post-dilation was performed at the surgeon’s discretion.
Definitions
The pre-intervention clinical variables followed the 
definitions published by the Society of Thoracic Sur-
geons,5 and surgical risk and possible post-intervention 
complications were determined in accordance with the 
logistic EuroSCORE.6
Transthoracic echocardiography was used to de-
fine the left ventricular end-systolic and end-diastolic 
diameter, left ventricular ejection fraction, aortic an-
nulus diameter, the diameter of the sinus of Valsalva, 
the ascending aorta diameter, the aortic valve area, the 
maximum and mean systolic gradients, the severity of 
aortic valve calcification, and the prosthetic valve area.
The degree of PAR after the procedure was evalu-
ated by transthoracic echocardiography performed by one 
of three experienced echocardiographists designated as 
members of the heart team and according to the criteria 
proposed by the Valve Academic Research Consortium – 
2 (VARC 2),7 classified as mild, moderate, or severe PAR 
using semi-quantitative and quantitative parameters.4,7,8
The study population was divided into two groups, 
according to the occurrence of post-procedure PAR: 
absent PAR/mild PAR and moderate PAR/severe PAR.
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Device success was considered when a single pros-
thesis was implanted properly and final results showed 
absence of prosthesis-patient mismatch, mean aortic 
transvalvular gradient < 20 mmHg, peak velocity < 3 
m/s, and mild aortic regurgitation at the maximum.7
Statistical Analysis
Continuous variables were shown as means and 
standard deviations, and categorical variables as fre-
quencies and percentages, compared, respectively, by 
the chi-squared test and Student’s t-test. 
A Cox logistic regression model was used to de-
termine independent predictors of moderate/severe PAR 
after transcatheter aortic valve implantation, including 
variables with P-values ≤ 0.2 in the univariate model.
Data were analyzed using SPSS, version 20 (SPSS 
Inc. – Chicago, USA). P-values < 0.05 were considered 
statistically significant.
RESULTS
Characteristics of the population and the 
procedure
Between June 2009 and February 2013, a total of 
182 patients with symptomatic severe aortic stenosis 
were evaluated for transcatheter aortic valve implanta-
tion. Of these, 112 patients (62%) underwent trans-
catheter aortic valve implantation at Instituto Dante 
Pazzanese de Cardiologia (n = 96, 86%) and at the 
Hospital do Coração da Associação do Sanatório Sírio 
(n = 16, 14%).
Basal clinical and echocardiographic characteristics 
of the 112 patients are shown in Table 1. The mean 
age of patients was 82.5 ± 3.9 years, and the majority 
(58.9%) were female. The mean logistic EuroSCORE was 
23.6 ± 13.4 and 88 (79%) were in functional class III 
– IV of the New York Heart Association (NYHA) criteria 
before the intervention.
The femoral vein was used in 91% of the patients, 
followed by transapical (6%), transaortic (2%), and 
subclavian (1%) routes. The CoreValve prosthesis 
was used in 76 patients (68.8%), whereas the Sapien 
XT™ was used in 21 (18.8%), and the Acurate TF™, 
in 15 (13.4%).
The maximum transaortic gradient before the 
procedure was 88 ± 24.3 mmHg and the mean was 
54.7 ± 15.3 mmHg, whereas the mean aortic valve 
area was 0.66 ± 0.15 cm². There was a decrease in 
the mean systolic gradient (pre = 54.7 ± 15.3 mmHg 
vs. post = 11.7 ± 4 mmHg; P < 0.01) and a gain in 
aortic valve area (pre = 0.66 ± 0.15 cm² vs. post = 
1.8 ± 0.3 cm²; P < 0.01) immediately after device 
implantation.
Device success was achieved in 94 patients (83.9%). 
There were two deaths during the procedure (1.8%), 
and five cases (4.5%) needed a second prosthesis due 
to inappropriate positioning of the first. 
Immediately after prosthesis implantation, 38 patients 
(33.9%) required post-dilation to reduce PAR, which 
occurred in two-thirds of the patients. At the end of 
the procedure, 52 patients (46.4%) had no PAR and 47 
(42%) had mild PAR, while moderate PAR was observed 
in 13 patients (11.6%). No patients had severe PAR.
Among the patients who developed moderate/severe 
PAR, the incidence of previous aortic valvuloplasty was 
higher (23.1% vs. 5.1%; P = 0.049). Additionally, pa-
tients in this group had smaller aortic valve area (0.67 
± 0.15 cm² vs. 0.59 ± 0.09 cm²; P = 0.007), and left 
ventricular ejection fraction was also lower (58.2 ± 12.6% 
vs. 48.6 ± 15.1%; P = 0.013) at the pre-intervention 
echocardiography. There was no difference between 
the groups regarding mean transaortic gradient, aortic 
annulus diameter, severity of aortic valve calcification, 
and incidence of bicuspid aortic valve.
Patients in both groups did not differ regarding the 
type of prosthesis used and the amount of contrast or 
procedure duration. Overall 30-day mortality of patients 
included in this study was 14.3%, with no statistical dif-
ference between groups. After the first 30 days, mortality 
from all causes, considering only patients who were 
discharged from the hospital, was 9.4%. The mid-term 
follow-up (16 ± 11 months) showed no difference in 
mortality between the groups (Table 2).
Multivariate analysis identified the following in-
dependent predictors of moderate/severe PAR: male 
gender (odds ratio [OR] 5.85; confidence interval [CI]: 
1.29 to 26.7; P = 0.022], aortic valvuloplasty prior 
to the percutaneous procedure (OR: 18.44; CI: 2.30 
to 147.85; P = 0.006), ejection fraction < 35 % (OR: 
4.160; CI: 1.014 to 17.064; P = 0.048), and presence of 
severe pulmonary hypertension (OR: 7.649; CI: 1.86 to 
31.51; P = 0.005). No variables of the procedure were 
associated with the occurrence of this complication.
DISCUSSION
The most important finding of the present study 
was that, although the occurrence of transcatheter aortic 
valve post-implantation PAR is common (53.6%), most 
cases are mild. In this study, there were no cases of 
severe PAR, and moderate PAR did not result in poor 
clinical outcome in the mid-term follow-up.
The incidence of moderate/severe PAR in the pres-
ent patients (11.6%) was similar to that observed in the 
Placement of Aortic Transcatheter Valve Trial (PARTNER),1,2 
a randomized study in which the incidence in the A 
and B cohorts was 12.2% and 11.8%, respectively. 
Regarding the high incidence of mild PAR (42%), se-
veral international registries have shown similar rates.9-11
Lluberas et al. 
Incidence and Clinical Predictors of Paravalvular Aortic
Rev Bras Cardiol Invasiva. 
2013;21(2):103-8
106
It has been speculated that the high incidence of 
PAR described after transcatheter aortic valve implan-
tation, a result of the incomplete apposition of the 
prosthesis in the aortic annulus, may be caused by the 
TABLE 1 
Basal clinical and echocardiographic characteristics
Total  
(n = 112)
Absent/mild 
paravalvular aortic 
regurgitation  
(n = 99)
Moderate/severe 
paravalvular aortic 
regurgitation  
(n = 13) P-value
Age, years 82.5 ± 3.9 82.8 ± 6.1 79.9 ± 8.9 0.28
Female gender, n (%) 66 (58.9) 61 (61.6) 5 (38.5) 0.1
Body mass index, kg/m2 25.7 ± 3.9 24.7 ± 6.2 25.9 ± 5.4 0.5
Logistic EuroSCORE 23.6 ± 13.4 23.1 ± 12.8 27.7 ± 17.8 0.2
Previous coronary artery bypass graft surgery, n (%) 24 (21.4) 21 (21.2) 3 (23.1) > 0.99
Previous valvuloplasty, n (%) 8 (7.1) 5 (5.1) 3 (23.1) 0.049
Chronic obstructive pulmonary disease, n (%) 14 (12.5) 12 (12.1) 2 (15.4) 0.67
Severe pulmonary hypertension, n (%) 37 (33) 30 (30.3) 7 (53.8) 0.1
Aortic valve area, cm2 0.66 ± 0.15 0.67 ± 0.15 0.59 ± 0.09 0.007
Mean pre-implantation transaortic gradient, mmHg 54.7 ± 15.3 55.2 ± 14.9 50.4 ± 18.1 0.29
Left ventricular ejection fraction, % 57.1 ± 13.2 58.2 ± 12.6 48.6 ± 15.1 0.013
Aortic annulus diameter, mm 22.4 ± 1.7 22.4 ± 1.7 22.4 ± 1.8 0.9
Left ventricular end-systolic diameter, mm 34.7 ± 9.1 33.7 ± 8.1 38.6 ± 17 0.39
Left ventricular end-diastolic diameter, mm 51.4 ± 7.1 50.1 ± 55.6 55.6 ± 9.9 0.13
Valsalva sinus diameter, mm 31.7 ± 4.7 31.6 ± 4.8 33.2 ± 2.4 0.29
Ascending aorta diameter, mm 34.5 ± 4 34.5 ± 4.4 34.5 ± 3.5 0.96
Severe aortic valve calcification, n (%) 47 (42) 41 (41.4) 6 (46.2) 0.73
Bicuspid aortic valve, n (%) 5 (4.5) 5 (5.1) 0 > 0.99
Mean post-implantation transaortic gradient, mmHg 11.7 ± 4 11.8 ± 4 10.8 ± 4.4 0.16
Prosthetic valve área, cm2 1.8 ± 0.3 1.8 ± 0.26 1.9 ± 0.25 0.4
TABLE 2 
Types of valve used and main characteristics of the procedure
Total  
(n = 112)
Absent/mild 
paravalvular aortic 
regurgitation (n = 99)
Moderate/severe 
paravalvular aortic 
regurgitation (n = 13) P-value
Types of valve, n (%) 0.76
CoreValve 76 (6.8) 67 (67.7) 10 (76.9)
Sapien XTTM 21 (18.8) 19 (19.2) 2 (15.4)
Acurate TFTM 15 (13.4) 14 (14.1) 1 (7.7)
Contrast volume, mL 145.1 ± 68.4 145.9 ± 71.7 139.2 ± 35.1 0.75
Duration of procedure, minutes 109 ± 41.5 107.2 ± 40.5 124.5 ± 49.2 0.24
30-day mortality, n (%) 16 (14.3) 14 (14.1) 2 (15.4) > 0.99
Mid-term mortality, n (%) 9 (8) 8 (8.1) 1 (7.7) > 0.99
heterogeneity of calcium distribution in the leaflets and 
annulus, or by the incorrect selection of the prosthesis 
diameter due to inadequate annulus measurement or 
the presence of extremely oval-shaped aortic annuli.4,12
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One of the main predictors of PAR described in the 
literature is the low ratio between prosthesis diameter 
and annulus diameter assessed by echocardiography (or 
cover index).13 In a study published in 2009, Detaint 
et al.13 reported the absence of PAR moderate/severe 
in patients with cover index > 8%. Therefore, it is 
believed that the oversizing of the annulus diameter 
when choosing the prosthesis could be a good measure 
to prevent significant PAR after implantation. Another 
way to minimize the occurrence of this complication 
would be to choose the prosthesis diameter based on the 
tomography, not on the transthoracic echocardiography, 
as some recent studies have shown this method to be 
more accurate in predicting the size of the annulus 
and the valve area.14-16 Currently, it is recommended 
to choose a prosthesis with a diameter at least 1 mm 
larger than the mean annulus diameter, or area 10% 
larger than the annulus area measured by multiple-slice 
computed tomography.15 However, it is worth mention-
ing that oversizing the prosthesis is not devoid of risk, 
as it can lead to annulus rupture.17
In the present series, the only echocardiographic 
predictor of PAR identified was the presence of severe 
left ventricular dysfunction (LV ejection fraction < 35%). 
Although the degree of calcification of leaflets and annulus 
was not a predictor of this event, it is worth noting that 
calcium assessment was performed qualitatively, based 
on transthoracic echocardiography evaluation. Several 
recent studies have used the Agatston score, defined 
by computed tomography, to quantitatively evaluate the 
valve apparatus degree of calcification. In this series, 
the degree of moderate/high calcification, which was 
more objectively assessed, emerged as an independent 
predictor of significant PAR.18,19
It is currently believed that the presence of PAR may 
have a negative impact on patient evolution.3,4,9,10,20,21 
In the recently published two-year evolution of the 
PARTNER study cohort A,3 the effect of PAR on mortality 
was proportional to PAR severity, and even the pres-
ence of mild PAR was associated with increased late 
mortality. Recent meta-analysis conducted by Athappan 
et al.21 demonstrated that moderate or severe PAR after 
transcatheter aortic prosthesis implantation is frequent 
(11.7%), and is considered an independent predictor 
of immediate (OR 2.95; CI: 1.73 to 5.02) as well as 
long-term mortality (hazard ratio [HR] 2.27; 95% CI: 
1.84 to 2.81). These results suggest that measures to 
improve PAR may lead to improved survival in patients 
submitted to transcatheter aortic valve implantation. It 
is noteworthy that the present series had no cases of 
severe PAR, and that moderate PAR was not associated 
with worse evolution in the mid-term.
CONCLUSIONS
In this initial experience of two national centers, 
the incidence of moderate/severe PAR was relatively 
low and comparable to other international samples. 
Male gender, history of previous percutaneous aortic 
valvuloplasty, and presence of severe pulmonary hy-
pertension and severe left ventricular dysfunction were 
identified as independent predictors of the occurrence 
of this complication.
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